(S)-ibuoprofen is a non-steroidal anti-inflammatory drug. It is commonly synthesized as a racemic mixture of (S)- and (R)-isomers. (S)-Ibuprofen is an enantiomer that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form. It is commonly synthesized as a racemic mixture of (S)- and (R)-isomers. (S)-Ibuprofen is an enantiomer that more potently inhibits COX activity, thromboxane formation, and platelet aggregation than the (R)-form.

[1] Evans AM, et al. Comparative pharmacology of S(+)-ibuprofen and (RS)-ibuprofen. Clin Rheumatol. 2001 Nov;20 Suppl 1:S9-14.

[2] Astrid Janssen, et al. Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment. Eur J Pharmacol. 2006 Jul 1;540(1-3):24-33.

[3] N Scheuren, et al. Modulation of transcription factor NF-kappaB by enantiomers of the nonsteroidal drug ibuprofen. Br J Pharmacol. 1998 Feb;123(4):645-52.

[4] Evans, A.M., Nation, R.L., Sansom, L.N., et al. Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclo-oxygenase inhibition: Relationship between inhibition of thromboxane production and the plasma unbound concentration of S(+)-ibuprofen. British Journal of Clinical Pharmacology 31(2), 131-138 (1991).